In brief: Ambri; QIC; Solbec; IDT
Monday, 13 December, 2004
Sydney-based biosensor developer Ambri (ASX:ABI) has made chief financial officer Jeff Carter redundant, citing a drive to redirect resources towards its biosensor platform. Ambri's current financial controller, Phillip Camilleri, will assume the role of company secretary, and take over responsibility of all financial matters.
The Queensland Investment Corporation (QIC) has become a substantial shareholder in Melbourne's Prima Biomed (ASX:PPR), with a holding of 5.6 per cent.
Perth-based biotech Solbec Pharmaceuticals (ASX:SBP) has signed up the Adelaide-based Institute of Drug Technology (ASX:IDT) to manufacture its Coramsine compound to FDA standard for Phase II clinical trials. The compound is currently being tested as a therapeutic for cancer and psoriasis.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
